Several additional agents blocking IL-1 are in clinical trials in several diseases (e.g., stroke, diabetes, and chronic inflammatory diseases) and target the IL-1 receptor, IL-1α, IL-1β, or caspase 1 (crucial for IL-1β activity). The gene discussed is IL1A; the disease is Stroke.